Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,351,728
  • Shares Outstanding, K 47,680
  • Annual Sales, $ 13,730 K
  • Annual Income, $ -120,320 K
  • 36-Month Beta 3.37
  • Price/Sales 98.46
  • Price/Cash Flow N/A
  • Price/Book 5.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.39
  • Low Estimate -0.91
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.66 +7.13%
on 10/11/18
33.75 -18.55%
on 09/20/18
-5.70 (-17.17%)
since 09/19/18
3-Month
25.66 +7.13%
on 10/11/18
36.70 -25.10%
on 07/20/18
-8.64 (-23.91%)
since 07/19/18
52-Week
20.29 +35.49%
on 11/08/17
45.02 -38.94%
on 03/09/18
+3.54 (+14.78%)
since 10/19/17

Most Recent Stories

More News
Recent Analysis Shows Lantheus, Editas Medicine, CorMedix, DXP Enterprises, Peabody Energy, and CommScope Holding Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Lantheus Holdings, Inc....

BTU : 35.56 (-0.84%)
COMM : 25.59 (-1.31%)
LNTH : 13.50 (-1.10%)
CRMD : 1.23 (-23.13%)
DXPE : 35.92 (-0.28%)
EDIT : 27.49 (-3.03%)
EDIT November 23rd Options Begin Trading

Investors in Editas Medicine Inc saw new options begin trading today, for the November 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain...

EDIT : 27.49 (-3.03%)
Editas Medicine Grows Scientific Leadership with Two New Appointments

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene therapy and oncology, joins the Company as Senior Vice President...

EDIT : 27.49 (-3.03%)
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch

Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to...

AAPL : 219.31 (+1.52%)
CRSP : 36.04 (-3.12%)
VRTX : 175.69 (-1.79%)
BBBY : 13.15 (-1.87%)
EDIT : 27.49 (-3.03%)
GILD : 73.27 (-1.21%)
NTLA : 22.19 (-4.31%)
Stocks Stall Ahead of Hike

Stocks Stall Ahead of Hike

HCA : 133.71 (-1.95%)
SLB : 58.47 (+0.07%)
BMRN : 103.22 (-0.58%)
EDIT : 27.49 (-3.03%)
QHC : 4.12 (-2.37%)
URBN : 36.14 (-1.98%)
Top Performing Active ETFs & Tesla's Best-Case Scenario

Neena Mishra talks with COO of ARK Investment Management, the firm behind most innovative ETFs that have consistently delivered excellent performance.

TSLA : 260.00 (-1.48%)
ARKW : 51.00 (-1.81%)
ARKG : 28.64 (-2.49%)
EDIT : 27.49 (-3.03%)
GBTC : 7.0500 (+1.00%)
AMZN : 1,764.03 (-0.38%)
SQ : 74.07 (-1.19%)
ARKK : 41.32 (-1.85%)
Editas Medicine Announces Transition of Chief Medical Officer

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D., will be stepping down from the Company at the end of the...

EDIT : 27.49 (-3.03%)
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration...

EDIT : 27.49 (-3.03%)
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why

Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.

AGN : 189.53 (+0.34%)
EDIT : 27.49 (-3.03%)
RHHBY : 30.5950 (+2.55%)
AMGN : 201.80 (-0.45%)
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

AZN : 39.21 (+0.67%)
NVO : 43.17 (-0.44%)
JNJ : 139.05 (-0.32%)
MRK : 72.35 (+0.19%)
AGN : 189.53 (+0.34%)
EDIT : 27.49 (-3.03%)
BMY : 54.30 (-3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 29.84
1st Resistance Point 28.67
Last Price 27.49
1st Support Level 26.83
2nd Support Level 26.16

See More

52-Week High 45.02
Fibonacci 61.8% 35.57
Fibonacci 50% 32.65
Fibonacci 38.2% 29.74
Last Price 27.49
52-Week Low 20.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar